90875-44-8 Usage
Description
5-chloro-2-morpholin-4-yl-aniline is a chlorinated aniline derivative with the molecular formula C10H13ClN2O. It features a morpholine ring attached to the 2-position and a chlorine atom at the 5-position. 5-chloro-2-morpholin-4-yl-aniline is recognized for its potential applications in medicinal chemistry, pharmaceuticals, agrochemicals, and dyes, due to its unique structural features and biological activities, including cytotoxic and antiproliferative properties that position it as a candidate for anticancer drug development.
Uses
Used in Pharmaceutical Industry:
5-chloro-2-morpholin-4-yl-aniline is used as a chemical intermediate in the synthesis of various pharmaceuticals, leveraging its structural attributes to contribute to the development of new medications.
Used in Agrochemical Industry:
In the agrochemical sector, 5-chloro-2-morpholin-4-yl-aniline serves as an intermediate, potentially contributing to the formulation of pesticides or other agrochemical products that require its specific chemical properties.
Used in Dye Industry:
5-chloro-2-morpholin-4-yl-aniline is utilized in the dye industry, where its chemical composition is employed in the creation of various dyes, taking advantage of its reactive sites for coloration purposes.
Used in Medicinal Chemistry Research:
5-chloro-2-morpholin-4-yl-aniline is used as a research compound in medicinal chemistry, where its cytotoxic and antiproliferative properties are explored for potential applications in anticancer drug development. Further research is necessary to fully elucidate its pharmacological and toxicological profiles, ensuring its safe and effective use in therapeutic contexts.
Check Digit Verification of cas no
The CAS Registry Mumber 90875-44-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,0,8,7 and 5 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 90875-44:
(7*9)+(6*0)+(5*8)+(4*7)+(3*5)+(2*4)+(1*4)=158
158 % 10 = 8
So 90875-44-8 is a valid CAS Registry Number.
InChI:InChI=1/C10H13ClN2O/c11-8-1-2-10(9(12)7-8)13-3-5-14-6-4-13/h1-2,7H,3-6,12H2
90875-44-8Relevant articles and documents
Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activity
Bailey, Brodie L.,Nguyen, William,Ngo, Anna,Goodman, Christopher D.,Gancheva, Maria R.,Favuzza, Paola,Sanz, Laura M.,Gamo, Francisco-Javier,Lowes, Kym N.,McFadden, Geoffrey I.,Wilson, Danny W.,Laleu, Beno?t,Brand, Stephen,Jackson, Paul F.,Cowman, Alan F.,Sleebs, Brad E.
, (2021/08/30)
Malaria is a devastating parasitic disease caused by parasites from the genus Plasmodium. Therapeutic resistance has been reported against all clinically available antimalarials, threatening our ability to control the disease and therefore there is an ongoing need for the development of novel antimalarials. Towards this goal, we identified the 2-(N-phenyl carboxamide) triazolopyrimidine class from a high throughput screen of the Janssen Jumpstarter library against the asexual stages of the P. falciparum parasite. Here we describe the structure activity relationship of the identified class and the optimisation of asexual stage activity while maintaining selectivity against the human HepG2 cell line. The most potent analogues from this study were shown to exhibit equipotent activity against P. falciparum multidrug resistant strains and P. knowlesi asexual parasites. Asexual stage phenotyping studies determined the triazolopyrimidine class arrests parasites at the trophozoite stage, but it is likely these parasites are still metabolically active until the second asexual cycle, and thus have a moderate to slow onset of action. Non-NADPH dependent degradation of the central carboxamide and low aqueous solubility was observed in in vitro ADME profiling. A significant challenge remains to correct these liabilities for further advancement of the 2-(N-phenyl carboxamide) triazolopyrimidine scaffold as a potential moderate to slow acting partner in a curative or prophylactic antimalarial treatment.
